These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 26113545

  • 1. A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy.
    Bonaud A, Bender S, Touchard G, Lacombe C, Srour N, Delpy L, Oblet C, Druilhe A, Quellard N, Javaugue V, Cogné M, Bridoux F, Sirac C.
    Blood; 2015 Aug 06; 126(6):757-65. PubMed ID: 26113545
    [Abstract] [Full Text] [Related]

  • 2. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management.
    Bridoux F, Javaugue V, Bender S, Leroy F, Aucouturier P, Debiais-Delpech C, Goujon JM, Quellard N, Bonaud A, Clavel M, Trouillas P, Di Meo F, Gombert JM, Fermand JP, Jaccard A, Cogné M, Touchard G, Sirac C.
    Kidney Int; 2017 Feb 06; 91(2):423-434. PubMed ID: 27773425
    [Abstract] [Full Text] [Related]

  • 3. Use of bortezomib in heavy-chain deposition disease: a report of 3 cases.
    Patel K, Dillon JJ, Leung N, Bomback AS, Appel GB, D'Agati V, Canetta PA.
    Am J Kidney Dis; 2014 Jul 06; 64(1):123-7. PubMed ID: 24613055
    [Abstract] [Full Text] [Related]

  • 4. Immunoglobulin heavy chain gene rearrangement in heavy chain deposition disease suggests it is a plasma cell disease: a case report.
    Rao Q, Xu R, Wan Q.
    J Int Med Res; 2022 Mar 06; 50(3):3000605221086428. PubMed ID: 35301906
    [Abstract] [Full Text] [Related]

  • 5. Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
    Alexander MP, Nasr SH, Watson DC, Méndez GP, Rennke HG.
    Am J Kidney Dis; 2011 Oct 06; 58(4):621-5. PubMed ID: 21944962
    [Abstract] [Full Text] [Related]

  • 6. Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice.
    Redfield RR, Lou Y, Rodriguez E, Rostami S, Parsons RF, Noorchashm H, Naji A, Abt PL.
    Transpl Immunol; 2013 Dec 06; 29(1-4):11-6. PubMed ID: 24103731
    [Abstract] [Full Text] [Related]

  • 7. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F, Delbes S, Sirac C, Pourreau F, Puyade M, Desport E, Jaccard A, Fermand JP, Touchard G.
    Presse Med; 2012 Mar 06; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [Abstract] [Full Text] [Related]

  • 8. Immunoglobulin light-chain toxicity in a mouse model of monoclonal immunoglobulin light-chain deposition disease.
    Bender S, Ayala MV, Bonaud A, Javaugue V, Carrion C, Oblet C, Rinsant A, Kaaki S, Oruc Z, Boyer F, Paquet A, Pons N, Hervé B, Ashi MO, Jaccard A, Delpy L, Touchard G, Cogné M, Bridoux F, Sirac C.
    Blood; 2020 Oct 01; 136(14):1645-1656. PubMed ID: 32559766
    [Abstract] [Full Text] [Related]

  • 9. Heavy chain deposition disease: recurrence in a renal transplant and report of IgG(2) subtype.
    Herzenberg AM, Kiaii M, Magil AB.
    Am J Kidney Dis; 2000 May 01; 35(5):E25. PubMed ID: 10793054
    [Abstract] [Full Text] [Related]

  • 10. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.
    Hainz N, Thomas S, Neubert K, Meister S, Benz K, Rauh M, Daniel C, Wiesener M, Voll RE, Amann K.
    Nephron Exp Nephrol; 2012 May 01; 120(2):e47-58. PubMed ID: 22286140
    [Abstract] [Full Text] [Related]

  • 11. A case of renal γ2 heavy-chain deposition disease accompanied by rapid progressive renal failure.
    Chen GT, Liao XH, Yan RY, Li Y, Zhang L.
    Ir J Med Sci; 2014 Jun 01; 183(2):319-21. PubMed ID: 23963539
    [Abstract] [Full Text] [Related]

  • 12. Heavy Chain Deposition Disease: Clinicopathologic Characteristics of a Chinese Case Series.
    Zhang Y, Li X, Liang D, Xu F, Liang S, Zhu X, Zheng N, Huang X, Liu Z, Zeng C.
    Am J Kidney Dis; 2020 May 01; 75(5):736-743. PubMed ID: 31699519
    [Abstract] [Full Text] [Related]

  • 13. Clinical remission and histopathological resolution of nodular lesions in a patient with gamma3 heavy-chain deposition disease.
    Soma J, Tsuchiya Y, Sakuma T, Sato H.
    Clin Nephrol; 2008 May 01; 69(5):383-6. PubMed ID: 18538103
    [Abstract] [Full Text] [Related]

  • 14. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
    Polzer K, Neubert K, Meister S, Frey B, Baum W, Distler JH, Gückel E, Schett G, Voll RE, Zwerina J.
    Arthritis Rheum; 2011 Mar 01; 63(3):670-80. PubMed ID: 21360496
    [Abstract] [Full Text] [Related]

  • 15. Proteasome inhibition for antibody-mediated allograft rejection.
    Sadaka B, Alloway RR, Shields AR, Schmidt NM, Woodle ES.
    Semin Hematol; 2012 Jul 01; 49(3):263-9. PubMed ID: 22726550
    [Abstract] [Full Text] [Related]

  • 16. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study.
    Joly F, Cohen C, Javaugue V, Bender S, Belmouaz M, Arnulf B, Knebelmann B, Nouvier M, Audard V, Provot F, Gnemmi V, Nochy D, Goujon JM, Jaccard A, Touchard G, Fermand JP, Sirac C, Bridoux F.
    Blood; 2019 Feb 07; 133(6):576-587. PubMed ID: 30578255
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I, Jordheim LP, Herveau S, Matera EL, Huber AL, Chettab K, Manié S, Dumontet C.
    Clin Cancer Res; 2013 Jul 01; 19(13):3556-66. PubMed ID: 23674497
    [Abstract] [Full Text] [Related]

  • 18. Articular, monoclonal gamma3 heavy-chain deposition disease: characterization of a partially deleted heavy-chain gene and its protein product synthesized in vivo and in vitro.
    Thompson KM, Sletten K, Brandtzaeg P, Källberg E, Wien TN, Husby G.
    Arthritis Rheum; 2003 Nov 01; 48(11):3266-71. PubMed ID: 14613292
    [Abstract] [Full Text] [Related]

  • 19. A case of heavy-chain deposition disease with good long-term renal survival and a literature review.
    Cai X, Zou W, Chen H, Xing C, Yu X.
    BMC Nephrol; 2024 Sep 19; 25(1):312. PubMed ID: 39300330
    [Abstract] [Full Text] [Related]

  • 20. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D, McConnell EJ, Dierlam L, Palamarchuk A, Lass A, Wójcik C.
    Int J Cancer; 2007 Jul 15; 121(2):431-41. PubMed ID: 17373661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.